AR080888A1 - Uso de un derivado de acido graso para producir una composicion oftalmica - Google Patents

Uso de un derivado de acido graso para producir una composicion oftalmica

Info

Publication number
AR080888A1
AR080888A1 ARP110101238A ARP110101238A AR080888A1 AR 080888 A1 AR080888 A1 AR 080888A1 AR P110101238 A ARP110101238 A AR P110101238A AR P110101238 A ARP110101238 A AR P110101238A AR 080888 A1 AR080888 A1 AR 080888A1
Authority
AR
Argentina
Prior art keywords
subject
program
temperature
patient
central area
Prior art date
Application number
ARP110101238A
Other languages
English (en)
Spanish (es)
Inventor
Yukihiko Mashima
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of AR080888A1 publication Critical patent/AR080888A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
ARP110101238A 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica AR080888A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32333810P 2010-04-12 2010-04-12
US32334210P 2010-04-12 2010-04-12
US32681110P 2010-04-22 2010-04-22
US36294510P 2010-07-09 2010-07-09
US40823710P 2010-10-29 2010-10-29

Publications (1)

Publication Number Publication Date
AR080888A1 true AR080888A1 (es) 2012-05-16

Family

ID=44798822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101238A AR080888A1 (es) 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica

Country Status (9)

Country Link
US (2) US20110275715A1 (https=)
EP (2) EP2558103A4 (https=)
JP (3) JP5686819B2 (https=)
KR (2) KR20130099812A (https=)
CN (2) CN102933217A (https=)
AR (1) AR080888A1 (https=)
CA (2) CA2795723A1 (https=)
TW (2) TW201204366A (https=)
WO (2) WO2011129457A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI508738B (zh) 2009-11-27 2015-11-21 R Tech Ueno Ltd 對乾眼症及／或角結膜障礙之處置有效的藥劑的篩選方法
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
WO2021087399A1 (en) * 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
CN115103842A (zh) 2020-02-06 2022-09-23 珀弗斯治疗股份有限公司 用于治疗眼部疾病的组合物
CA3218251A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
JP2024525589A (ja) 2021-07-09 2024-07-12 アリゴス セラピューティクス インコーポレイテッド 抗ウイルス化合物
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
FI131849B1 (en) * 2024-09-10 2026-01-09 Pixieray Oy METHOD AND OPTICAL DEVICE FOR MONITORING THE USE OF EYE DROPS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771130B2 (en) * 2000-01-18 2004-03-11 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
WO2005018646A1 (ja) * 2003-08-21 2005-03-03 Sucampo Ag 眼科用組成物
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
US20110275715A1 (en) 2011-11-10
CA2795723A1 (en) 2011-10-20
CN102946883A (zh) 2013-02-27
EP2558104A1 (en) 2013-02-20
JP2016026182A (ja) 2016-02-12
CN102933217A (zh) 2013-02-13
US20110275711A1 (en) 2011-11-10
JP5878128B2 (ja) 2016-03-08
EP2558103A1 (en) 2013-02-20
EP2558104A4 (en) 2013-12-11
TW201141486A (en) 2011-12-01
CA2795720A1 (en) 2011-10-20
WO2011129461A1 (en) 2011-10-20
WO2011129457A1 (en) 2011-10-20
KR20130050939A (ko) 2013-05-16
EP2558103A4 (en) 2013-09-25
JP2013528563A (ja) 2013-07-11
JP5686819B2 (ja) 2015-03-18
KR20130099812A (ko) 2013-09-06
TW201204366A (en) 2012-02-01
JP2013523601A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
AR080888A1 (es) Uso de un derivado de acido graso para producir una composicion oftalmica
Benito et al. Objective optical assessment of tear-film quality dynamics in normal and mildly symptomatic dry eyes
Colak et al. Comparison of corneal topographic measurements and high order aberrations in keratoconus and normal eyes
Orucoglu et al. Analysis of age, refractive error and gender related changes of the cornea and the anterior segment of the eye with Scheimpflug imaging
Wolsley et al. Investigation of changes in the myopic retina using multifocal electroretinograms, optical coherence tomography and peripheral resolution acuity
Pinero et al. Ocular scattering
Low et al. The outcomes of primary pediatric keratoplasty in Singapore
BR112013021153A2 (pt) dispositivo e métodos de rastreamento ocular de fotorrefração
MX2021014958A (es) Sistema y metodo para prueba multimodal de enga?o calificado por aprendizaje de maquina.
Read Ocular and environmental factors associated with eye growth in childhood
Loreck et al. Morning myopic shift and glare in advanced Fuchs endothelial corneal dystrophy
Hilmi et al. Measurement of contrast sensitivity using the M&S Smart System II compared with the standard Pelli–Robson chart in patients with primary pterygium
Chakraborty et al. Diurnal variations in ocular aberrations of human eyes
Qiao et al. Full-field strain mapping for characterization of structure-related variation in corneal biomechanical properties using digital image correlation (DIC) technology
Hussein et al. The long-term outcomes in children who are not compliant with spectacle treatment for accommodative esotropia
Aldossari et al. Effect of accommodation on peripheral eye lengths of emmetropes and myopes
De La Cera et al. Longitudinal changes of optical aberrations in normal and form-deprived myopic chick eyes
Gillmann et al. Relationship between contact lens sensor output parameters and visual field progression in open-angle glaucoma: assessment of a practical tool to guide clinical risk-assessment
Ortiz et al. Quantification and monitoring of visual disturbances for patients with cataracts using Halo v1. 0 software.
van Bree et al. Straylight values after refractive surgery: screening for ocular fitness in demanding professions
Arranz-Márquez et al. Disminución de la agudeza visual
ES2441669A1 (es) Método para la detección de pérdidas de función visual.
Benzoni et al. Does the dynamic cross cylinder test measure the accommodative response accurately?
Yeh et al. The genetic effect on refractive error and anterior corneal aberration: twin eye study
Kuo et al. The ocular biometric and corneal topographic characteristics of high-anisometropic adults in Taiwan

Legal Events

Date Code Title Description
FB Suspension of granting procedure